UB Paderborn / Katalog / Suche / in CDI

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

Clinical infectious diseases, 2020-04, Vol.70 (8), p.1525-1533

2020

Volltextzugriff (PDF)

Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults

Clinical infectious diseases, 2008-06, Vol.46 (11), p.1769-1781

2008

Volltextzugriff (PDF)

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

The New England journal of medicine, 2017-12, Vol.377 (25), p.2433-2444

2017

Volltextzugriff (PDF)

Long-term safety from the raltegravir clinical development program

Current HIV research, 2011-01, Vol.9 (1), p.40

2011

Volltextzugriff (PDF)

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium

Annals of the New York Academy of Sciences, 2011-03, Vol.1222 (1), p.83-89

2011

Volltextzugriff (PDF)

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

American journal of transplantation, 2020-06, Vol.20 (6), p.1703-1711

2020

Volltextzugriff (PDF)

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Clinical and Vaccine Immunology, 2009-09, Vol.16 (9), p.1285-1292

2009

Volltextzugriff (PDF)

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

AIDS (London), 2011-07, Vol.25 (11), p.1365-1369

2011

Volltextzugriff (PDF)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

Open forum infectious diseases, 2017-01, Vol.4 (1), p.ofw047-ofw047

2017

Volltextzugriff (PDF)

Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor—Naive Adults with Advanced HIV Infection

Clinical infectious diseases, 2003-10, Vol.37 (8), p.1119-1124

2003

Volltextzugriff (PDF)

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

AIDS research and human retroviruses, 2009-01, Vol.25 (1), p.103

2009

Volltextzugriff (PDF)

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

Open forum infectious diseases, 2014-03, Vol.1 (1), p.ofu016-ofu016

2014

Volltextzugriff (PDF)

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Clinical infectious diseases, 2015-06, Vol.60 (12), p.1842-1851

2015

Volltextzugriff (PDF)

Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials

AIDS (London), 2001-08, Vol.15 (12), p.1584-1586

2001

Volltextzugriff (PDF)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S56-S57

2018

Volltextzugriff (PDF)

Wegener granulomatosis: an analysis of 158 patients

Annals of internal medicine, 1992-03, Vol.116 (6), p.488

1992

Volltextzugriff (PDF)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S311-S311

2017

Volltextzugriff (PDF)

Vasculitic syndromes: Editorial overview

Current opinion in rheumatology, 1993-01, Vol.5 (1), p.1-4

Leavitt, Randi Y

1993

Volltextzugriff (PDF)

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Journal of Virology, 1996-12, Vol.70 (12), p.8270-8276

1996

Volltextzugriff (PDF)

Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis

American journal of respiratory and critical care medicine, 1995-03, Vol.151 (3 Pt 1), p.795

1995

Volltextzugriff (PDF)

Wegenerʼs granulomatosis

Current opinion in rheumatology, 1991-02, Vol.3 (1), p.8-14

1991

Volltextzugriff (PDF)

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Clinical and vaccine immunology, 2010-01, Vol.17 (1), p.204-204

2010

Volltextzugriff (PDF)

Wegener granulomatosis in children and adolescents: Clinical presentation and outcome

The Journal of pediatrics, 1993, Vol.122 (1), p.26-31

1993

Volltextzugriff (PDF)

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3

Revista do Instituto de Medicina Tropical de São Paulo, 2000-02, Vol.42 (1), p.27-36

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Long-term safety from the raltegravir clinical development program

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor—Naive Adults with Advanced HIV Infection

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients

Wegener granulomatosis: an analysis of 158 patients

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)

Vasculitic syndromes: Editorial overview

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis

Wegenerʼs granulomatosis

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Wegener granulomatosis in children and adolescents: Clinical presentation and outcome

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3

Suchergebnisse filtern